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Abstract
Background: Beneficial effects of short-term erythropoietin (EPO) therapy have been demonstrated in several animal
models of acute neurologic injury, including experimental autoimmune encephalomyelitis (EAE)-the animal model of
multiple sclerosis. We have found that EPO treatment substantially reduces the acute clinical paralysis seen in EAE mice and
this improvement is accompanied by a large reduction in the mononuclear cell infiltration and downregulation of glial MHC
class II expression within the inflamed CNS. Other reports have recently indicated that peripherally generated anti-
inflammatory CD4+Foxp3+ regulatory T cells (Tregs) and the IL17-producing CD4+ T helper cell (Th17) subpopulations play
key antagonistic roles in EAE pathogenesis. However, no information regarding the effects of EPO therapy on the behavior
of the general mononuclear-lymphocyte population, Tregs or Th17 cells in EAE has emerged.
Methods and Findings: We first determined in vivo that EPO therapy markedly suppressed MOG specific T cell proliferation
and sharply reduced the number of reactive dendritic cells (CD11c positive) in EAE lymph nodes during both inductive and
later symptomatic phases of MOG35–55 induced EAE. We then determined the effect in vivo of EPO on numbers of peripheral
Treg cells and Th17 cells. We found that EPO treatment modulated immune balance in both the periphery and the inflamed
spinal cord by promoting a large expansion in Treg cells, inhibiting Th17 polarization and abrogating proliferation of the
antigen presenting dendritic cell population. Finally we utilized tissue culture assays to show that exposure to EPO in vitro
similarly downregulated MOG-specific T cell proliferation and also greatly suppressed T cell production of pro-inflammatory
cytokines.
Conclusions: Taken together, our findings reveal an important new locus whereby EPO induces substantial long-term tissue
protection in the host through signaling to several critical subsets of immune cells that reside in the peripheral lymphatic
system.
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Introduction
Most autoreactive T cells are negatively selected and eliminated
during thymic development in a process called central T cell
tolerance [1,2]. However, the central selection process is often
incomplete and autoreactive lymphocytes with pathogenic poten-
tial still circulate in the peripheral lymphoid tissues [3,4]. When
abnormally activated by ‘‘self’’ antigens or mimics, these
autoreactive T cells may attack self-organs thereby participating
in the development of autoimmune disorders. This fact is
supported by the demonstrable ability to induce a variety of
autoimmune diseases in rodents using appropriate immunization
protocols. Th17 cells are a unique subset of CD4+ TH cells and
recent studies suggest that Th17 cells have an important
pathogenic role in T cell mediated autoimmune disease and tissue
inflammation [5,6,7,8,9]. Another distinct T cell population
(CD4+Foxp3+) called regulatory T cells (Tregs) has also attracted
attention recently because it plays an important role in
maintenance of peripheral tolerance and in controlling the
destructive self-reactive T cells found in autoimmune animal
models of arthritis, multiple sclerosis, diabetes, and inflammatory
bowel disease [10,11,12]. Modulating the Treg population and
other associated factors may prove to be an effective new therapy
for autoimmune disease.
EAE is a central nervous system inflammatory demyelinating
disease of animals that attacks the spinal cord and brain white
matter [13,14]. The CNS white matter histopathology in EAE
animals is similar to that in multiple sclerosis (MS) in that there are
prominent white matter perivascular infiltrating T cells, myelin
destruction and associated axonal damage. Autoreactive CD4 and
CD8 T cells are believed to be involved in the pathogenesis of
EAE and MS [15,16,17,18]. Subcutaneous injection of myelin
antigen into animals or adoptive transfer of purified MOG-specific
T cells obtained from EAE mice into naı¨ve mice can both induce
the disease [18,19]. Proinflammatory cytokines, especially IL-2
and TNF-alpha have been demonstrated to play a significant role
in both the induction phase and later clinical stages of EAE
pathogenesis [20,21,22].
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Erythropoietin (EPO), a 165 amino acid glycoprotein cytokine,
has been used extensively for the treatment of anemia in humans
and has been shown to have the capacity to induce neuroprotec-
tion in a disparate variety of animal models of nervous system
disease [14,23,24,25]. We have previously demonstrated that EPO
therapy is of substantial clinical benefit and EPO treatment
significantly reduces mononuclear cell infiltration, downregulates
MHC class II expression, and induces axonal protection within the
brain and spinal cord of animals with EAE [14].
The mechanism by which EPO induces neuroprotection in
EAE remains unclear. In this study, we characterized the effect of
EPO on immunogenesis within the peripheral lymphoid tissues
and the impact of EPO therapy on infiltrating inflammatory cells
within the CNS target organ using the EAE mouse model. We
found that EPO therapy exerts unexpectedly profound biologic
effects within the peripheral lymphoid system tissues and acts as a
potent molecular check on inflammation by blocking dendritic cell
expansion and T cell proliferation while inducing rapid expansion
of the Treg cell population and a corresponding reduction in Th17
cells. This comprehensive immune modulating mechanism likely
accounts for the bulk of the EPO neuroprotective effects induced
in the EAE animal model.
Results
EPO down-regulates MOG-specific T cell proliferation in
vitro and suppresses T cell cytokine production
Autoreactive T cells are believed to play key roles in the
pathogenesis of EAE. Two major pathogenic MOG peptide
epitopes (MOG40–54 and MOG44–54) have been used to construct
peptide/H-2Db dimeric complexes to quantify the encephalito-
genic CD8 T cell subsets [19]. We first determined if peripheral
MOG-specific CD8 T cells in MOG35–55 immunized mice could
be quantified by flow cytometry. As expected, less than 0.5% of
normal mouse spleen mononuclear cells stained positive with the
MOG44–54/H-2D
b dimer (Fig. 1a). By contrast, about 3% of
spleen mononuclear cells obtained from MOG35–55 peptide
immunized mice were double positive for MOG44–54/H-2D
b
dimer and CD8 staining 7 days post immunization (Fig. 1a). In
contrast, we found less than 0.6% non-specific binding to a control
NP366–374/H-2D
b dimer by the same EAE splenic single-cell
suspensions (Fig. 1a). Adoptive transfer of these EAE-MOG
induced T cells generated clinical EAE in naı¨ve normal C57 mice
and CNS pathologic changes in recipient mouse spinal cords
about 14 days after adoptive transfer (data not shown).
To determine whether EPO exerted a direct effect on MOG-
specific T cells and their cytokine profile, we enriched EAE MOG-
specific T cells in long term culture and then treated them with
EPO (1, 10,100 U/ml) for 48–72 hrs. Culture supernatants were
collected for cytokine quantification and the remaining cell
population was reacted with peptide/dimer complexes and anti-
CD8 antibody to determine the number of MOG specific T cells.
EPO (1 U/ml) induced a substantial reduction (*p,0.005) in
major pro-inflammatory cytokines (IL-6, TNF-a, IL-2 and IFNc)
(Fig. 1b). A mild reduction in level of GM-CSF (p = 0.09) and
insignificant changes in IL-4, IL-10, IL-5 and IL-12 levels were
observed (Fig. 1b). We also found a marked reduction in numbers
of MOG antigen specific T cells in EPO treated samples
(p,0.005) and this correlated well with the marked reduction in
multiple pro-inflammatory cytokine levels (Fig. 1c). The EPO-
mediated downregulation of MOG-specific T cell proliferation
was dose related and the most effective reductions were observed
in lower dose EPO treated samples (1 and 10 U/ml), whereas high
dose EPO (100 U/ml) in cell culture had little effect on numbers of
MOG-T cells and levels of cytokine (data not shown).
EPO treatment reduces inflammatory mononuclear cell
(MNC) numbers in peripheral lymph nodes
We previously reported that both disease severity and duration
of maximum impairment were reduced when EPO therapy was
initiated after onset of neurologic impairment in MOG-EAE mice
[14]. Others have reported that early EPO treatment during the
EAE induction period (prior to or immediately after MOG35–55
immunization) was also effective in delaying disease onset and
reducing disease severity [23,25]. To assess if EPO treatment post
MOG-immunization had direct immunomodulating effects within
the peripheral lymphoid tissue of EAE mice, EPO or sham PBS
treatment was initiated 7 days post immunization and draining
inguinal lymph nodes (DILNs) from EPO or sham treated EAE
mice were subsequently obtained at different time points. The total
number of MNCs, CD4, CD8 T cells and CD11c positive
dendritic cells as well as MHC class I and class II expression on the
DILN cells was quantified by flow cytometry at different times.
Table 1 shows a greatly expanded inflammatory mononuclear cell
population occurs in sham treated EAE mice on day 11 post
MOG-immunization compared to normal controls and the
inflammatory cell subset numbers also remained higher than
normal on day 17. EPO treatment for as few as 3 days (day 11 post
MOG-immunization) significantly reduced all subsets of the
inflammatory cells (p,0.001) and a similar reduction in cell
subsets was observed on day 17. We also found that EPO
treatment for 3 days down-regulated MHC class I and II
expression in DILN mononuclear cells (Fig. 2a, p,0.001). About
4.0% of the spleen mononuclear cells were double positive for
CD3 and MOG44–54 dimer binding and EPO treatment
significantly reduced the MOG-specific T cell population in
EAE mice (Fig. 2b, p,0.01).
We next determined if EPO had similar immunomodulating
effects on the peripheral lymphoid tissues when EPO treatment
was started at the same time as the mice received MOG peptide
immunization. Mice were immunized with MOG35–55 and then
divided randomly into two groups that received either immediate
EPO treatment (5000 U/kg/day 63 followed by 1000 U/kg/
day63) or PBS sham treatment over the same period for a total of
6 days. DILNs and spleens were collected from mice on day 7.
Fig. 3a shows greatly enlarged DILNs were induced in sham
treated MOG-EAE by 7 days post immunization. In contrast, the
size of DILNs in EPO treated EAE mice was much smaller and
resembled lymphoid tissue from normal mice. When total
mononuclear cells were quantified from single cell suspensions of
harvested inguinal lymph nodes, we again found much higher cell
numbers in sham treated EAE mice compared to EPO treated
EAE mice or to normal mice (Fig. 3b). EPO therapy significantly
reduced the population of CD11c positive DCs (Fig. 3c) and the
numbers of CD4, CD8 T cells (data not shown).
EPO treatment induces peripheral Treg cell expansion
and blocks Th17 cell polarization in MOG-EAE mice
Brief treatment with EPO during the EAE induction period for
6 days significantly delayed onset of clinical neurologic deficit
compared to sham treated EAE mice (P,0.05). This brief course
of EPO treatment induced a neuroprotective effect that was
sustained over a long term clinical follow-up period of 45 days
(Fig. 4a). Both Treg and Th17 cells are believed to be critical for
control of the autoimmune inflammatory process in EAE and
other autoimmune diseases including collagen-induced arthritis
EPO: Immune Modulation
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and inflammatory bowel disease [26,27,28,29]. We suspected that
EPO-mediated neuroprotection in EAE might be in part a
consequence of an immunomodulating effect on the balance of
Treg and Th17 cell populations in either peripheral lymphoid
tissue or the central nervous system target organ. We found a
significant reduction in the number of peripheral Treg cells and a
remarkable increase in peripheral Th17 cells during the early
symptomatic phase (day 16 post MOG-immunization) in sham
treated EAE animals compared to normal controls (Fig. 4b–c).
EPO treatment for 6 days induced significant expansion in Treg
cells within the DILNs (Fig. 4b–c) and significantly reduced the
polarization of Th17 cells in the periphery.
To serially quantify the Tregs, Th17 cells and MOG40–54-
specific T cells in EAE animals after treatment with either EPO or
sham PBS, fresh MNCs from DILNs of MOG-immunized mice
were obtained at different time points after initiation of either EPO
or sham PBS treatment. We found sustained reductions in Treg
cells during the early EAE induction period, the symptomatic
Figure 1. EPO down-regulates proliferation of MOG-specific T cells and suppresses T cell cytokine production. a) Single cell
suspensions of hyperimmune EAE spleen were prepared 7 days post MOG peptide immunization and quantified by flow cytometry for CD8 and
MOG44–54/H-2Db dimer double positive binding. In normal mice, 0.42% of splenic CD8 cells bound to the MOG44–54/H-2Db dimer (left side), whereas
an 8-fold increase in MOG44–54/H-2Db dimer positive staining occurred in CD8 T cells obtained from MOG35–55 immunized EAE animals (middle). In
contrast, when a non-specific control peptide was tested, only 0.6% of CD8 cells exhibited non-specific binding to the NP366–374 dimer (right). b & c)
MOG-EAE antigen specific T cells were enriched by exposure to antigen in long term tissue culture, and then exposed to EPO (1 or 10 U/ml) for
72 hrs. Supernatants were collected from the cultured MOG-T cells for cytokine profile analysis and the remaining cells were quantified for number of
CD8 and MOG44–54/H-2Db dimer double binding cells after exposure to EPO or control treatment. EPO induced a marked decrease in pro-
inflammatory cytokine production (black bars) when compared to controls (white bars). EPO at 1 U/ml induced a substantial decline in the MOG-
specific CD8 T cell population (c-middle panel). Some of the MOG44–54-peptide/H-2Db dimer positive, non-CD8 T cell (including portion of CD11c
positive cells) populations were also reduced by EPO treatment (c-middle panel). Each data point is the mean6SEM of three experiments performed
in triplicate. *, p,0.005.
doi:10.1371/journal.pone.0001924.g001
EPO: Immune Modulation
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phase as well as the late chronic phase in sham treated EAE
animals compared to normal controls (p,0.01). The reduction in
peripheral Treg cells in sham treated EAE was more apparent on
day 7 (before onset of clinical signs) and on day 16 (early acute
clinical disease) than later in the disease course. EPO treatment
induced a significant expansion in Treg cells within the peripheral
lymphoid tissue that could be detected at a very early stage
(Fig. 5a). The increased number of peripheral Tregs was even
more prominent 5 weeks after termination of EPO treatment
(p,0.001). The Th17 cell population in peripheral lymphoid
tissue remained elevated in sham treated EAE mice during both
the early and late stages of EAE (Fig. 5b), as expected. The Th17
expansion was associated with a fulminant inflammatory response
following MOG-immunization in untreated EAE animals and was
associated with severe clinical disease. EPO therapy significantly
blocked polarization of peripheral Th17 cells (p,0.001). In
addition, early EPO treatment again reduced peripheral
MOG40–54/H-2Db antigen specific T cells while inducing
sustained suppression of the MOG-T effector cell population
(p,0.001, Fig. 5c). The expansion in peripheral Treg cells, and
Figure 2. In vivo effect of EPO treatment on MHC expression and number of MOG antigen specific T cells in inguinal lymph nodes.
EPO treatment was started 7 days after mice received MOG35–55 immunization. Bilateral draining inguinal lymph nodes (DILNs) were obtained from
mice on day 11 (after 3 day treatment with either EPO at 5000 U/kg/day or sham treatment with PBS) and single cell suspensions were prepared. a)
EPO treatment down-regulated mononuclear cell MHC class I (left) and class II (right) expression in lymph nodes from EAE mice. b) Less than 0.7% of
single cells from normal mouse inguinal lymph nodes were double-positive for MOG44–54 dimer and anti-CD3 antibody. In contrast, about 4% of
single cell suspensions from sham treated EAE mice were positive for FITC-CD3 and PE-MOG40–54/H-2Db dimer double staining (middle), whereas EPO
treatment reduced in vivo proliferation of MOG-specific T cells back to 1.5% (right).
doi:10.1371/journal.pone.0001924.g002
Table 1. EPO reduces total number of Mononuclear and T cells in EAE lymph nodes
Day 11 a Day 17 b
Cells (6106) Normal EAE-PBS EAE-EPO Normal EAE-PBS EAE-EPO
Mononuclear cells (MNCs) 6.1560.79c 37.6069.34d 6.7661.45 5.3060.87 23.664.78d 10.8663.52
CD4 T cells 2.1560.17 11.7662.05d 5.5860.89 2.160.56 4.2460.52e 3.3460.42
CD8 T cells 1.5361.71 8.460.52d 1.6460.18 1.7160.36 3.6660.59e 2.4460.21
Dendritic cells (DC) 0.1660.01 1.5960.12d 0.0760.01 0.1560.02 0.760.19d 0.260.01
a, bEPO or sham PBS daily treatment for 3 days was initiated 7 days post MOG-immunization. Mice (n = 6/group) were sacrificed on day 11 (a) or day 17 (b). DILNs were
harvested for cell quantification. Normal mice (n = 6) were used as controls.
cmean6SEM
dp,0.001 (sham PBS treated EAE vs NL or EPO-treated EAE mice)
ep,0.05 (sham PBS treated EAE vs NL mice)
doi:10.1371/journal.pone.0001924.t001
EPO: Immune Modulation
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marked reduction in peripheral Th17 and MOG40–54/H-2Db
specific T cells as well as the abrogation of dendritic cell
proliferation that occurred in EPO treated EAE mice clearly
correlated well with less severe clinical disease.
EPO treatment increased numbers of Treg cells and
reduced numbers of Th17 cells in MOG-EAE mouse spinal
cord
During the EAE induction phase, we found increased numbers of
inflammatory cells within spinal cords shortly before onset of
paralysis in sham treated EAE mice (about day 7–10), In contrast far
fewer infiltrating inflammatory cells were found in spinal cords from
EPO treated EAE mice. The number of CNS infiltrating
inflammatory cells was 4–5 times greater in sham treated EAE
mice compared to EPO treated animals when animals were studied
either at their peak clinical neurologic deficit or at later stages of EAE
(day 45). Detailed analysis of the inflammatory cells infiltrating the
CNS again revealed higher numbers of Treg cells in EPO treated
animals (Fig. 6a). The increased Treg cell population in the diseased
CNS similarly became more evident in late stages of the disease,
suggesting that Treg cells continue to migrate into the CNS for a
lengthy period of time (Fig. 6a). The increased number of anti-
inflammatory Treg cells infiltrating the spinal cord in EPO-treated
EAE animals was confirmed by direct immunohistochemical
staining for Treg cells (mAb against Foxp3+) on paraffin-embedded
spinal cord sections. Fig. 6 (b–c) shows a substantial increase in
infiltrating Treg cells within the spinal cord of EPO-treated EAE
(Fig. 6b) compared to sham treated EAE (Fig. 6c).
Significantly increased Th17 cells within the CNS were found at
the time animals developed clinical disease, and higher numbers of
Th17 cells in spinal cords were notably associated with more
severe clinical neurologic deficits in EAE animals. EPO treatment
reduced infiltrating Th17 cells in the diseased CNS (Fig. 6d) as
previously described in peripheral lymph nodes. Similarly, a
marked reduction in MOG-T effector cells within the CNS as
judged by the antigen dimer assay was observed in EPO treated
animals compared to sham treated EAE controls (Fig. 6e).
Discussion
EAE is a commonly studied animal model of acute central
nervous system inflammatory demyelinating disease, and it is
believed that autoreactive T cells and proinflammatory cytokines
play key roles in the early inductive phase and later paralytic stages
of EAE pathogenesis [16,30,31]. We have previously demonstrat-
ed that EPO treatment blocks clinical progression and blunts the
disease pathology in MOG-induced EAE [14]. In this study, we
utilized in vitro and ex vivo methods to explore potential
mechanisms by which EPO mediates neuroprotection in the
EAE animal model. We found in vitro that exposure of enriched
EAE splenic T cell cultures to EPO significantly downregulated
autoreactive T cell numbers and their production of proinflam-
matory cytokines. EPO treatment in EAE mice also greatly
reduced total MNC numbers in lymphoid system tissue, including
the antigen presenting DC population as well as T cells. Most
importantly, EPO treatment also resulted in a marked expansion
in the Treg cell population and a corresponding reduction in Th17
cells and MOG-specific T cells within both peripheral lymphoid
tissue and diseased EAE spinal cords. By modulating multiple
functional immune cell types and their corresponding cytokines,
EPO therapy transformed a significantly destabilized autoimmune
process in EAE animals into one of relatively normal immune
status. As a consequence, less severe neurologic deficits and less
neuropathologic abnormalities were found in EPO treated EAE
animals compared to sham treated controls.
Traditionally CD4 T cells have been considered to be the
critical element in EAE pathogenesis, but recent studies have
indicated that CD8 cells may also play an important role in EAE
induction and disease progression [16,17,18,30]. Studies on
human CNS tissue also support the notion that myelin-specific
CD8 T cells in human MS lesions may be encephalitogenic
[30,32]. A truncated MOG peptide library derived from MOG35–
55 has been previously used to identify the key peptide epitopes for
pathogenic T cells and two major MOG peptide epitopes within
MOG40–54 have been found to be pathogenic for EAE induction
[19]. To determine if EPO had a direct impact on MOG-specific
T cells and their associated cytokines, we studied MOG-specific T
cells in culture after exposure to EPO or medium alone. Low dose
EPO significantly reduced the proliferation of MOG44–54/H-2D
b
specific CD8 T cells, while much higher doses (100 U/ml) had
only minor or no effect. A similar J-shaped dose-response curve
following EPO exposure has been previously observed in MHC
class II expression on a mouse EOC microglial cell line [14].
Figure 3. Early EPO treatment sharply reduced total numbers
of inflammatory cells and limited expansion of the dendritic
cell population in DILNs during the EAE induction phase. C57
mice received EPO or PBS sham treatment starting on the day of MOG-
immunization for 6 days and lymph nodes were obtained on day 7. a)
Significantly enlarged inguinal lymph nodes were observed in control
sham treated MOG-EAE mice (middle), whereas much smaller nodes
were found in EPO treated EAE mice (right) similar in size to nodes from
normal animals (left). b) Total MNCs were quantified from single cell
suspensions of DILNs after lysis of RBCs. Greatly increased inflammatory
mononuclear cell numbers were observed in sham treated EAE lymph
nodes compared to DILNs from EPO treated EAE mice or normal mice.
c) Cells were reacted with fluorophore labeled mAbs specific for surface
markers (MHC class II and CD11c) and analyzed by flow cytometry. Note
that the large expansion in dendritic cell population found in sham
treated EAE mice was dramatically suppressed by EPO therapy. Data
represents mean6SEM for 6 individual mice. **, p,0.0001.
doi:10.1371/journal.pone.0001924.g003
EPO: Immune Modulation
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Figure 4. EPO induced sustained immuno/inflammatory modulation by expanding peripheral Treg cell numbers and reducing Th17
positive cells. Mice were immunized with MOG and received daily EPO treatment for 6 days (day1–6). a). EPO therapy for 6 days delayed onset of
clinical neurologic signs in animals and reduced the magnitude of clinical deficit in EAE mice (N) compared to sham treated control (#) EAE mice (*,
p,0.05). The clinical score was determined as the mean6SEM of 8 mice per group. Data represents the mean6SEM of 8 individual mice. b–c) DILNs
were obtained from mice after 6 days treatment with either EPO or PBS. Cells were quantified for number of Tregs (CD4+Foxp3+) and Th17 by flow
cytometry. Panel b shows that about 3.4% Treg cells were detectable in normal mouse inguinal lymph node (left). A reduced number (2.4%) of Treg
cells was detected in sham treated EAE control mice nodes (middle), whereas EPO therapy induced a 2-fold increase in Foxp3+ Treg cells on day 16
compared to sham treatment (right). Panel c shows,0.2% of normal healthy lymph node cells stained positive for Th17 (left). Numbers of peripheral
Th17 cells greatly increased on day 16 (15-fold) in EAE mice treated with PBS (middle, 3.2%). In marked contrast, EPO therapy (right) sharply reduced
the number of peripheral Th17 cells in MOG-immunized animals.
doi:10.1371/journal.pone.0001924.g004
EPO: Immune Modulation
PLoS ONE | www.plosone.org 6 April 2008 | Volume 3 | Issue 4 | e1924
Figure 5. EPO treatment induced peripheral Treg cell expansion while reducing MOG-specific T cells and Th17 positive cells in
peripheral lymphoid tissues.Mice were immunized with MOG and received daily EPO treatment for 6 days (day1–6). DILNs and spinal cords were
obtained at three different time points (day 7, day 16 and day 45) from mice treated with EPO or sham treated with PBS. Cells were quantified for
number of Tregs (CD4+Foxp3+), Th17 and MOG-antigen specific T cells by flow cytometry. a) There were reduced numbers of Treg cells in DILNs from
sham treated EAE mice at early stages (day 7) as well as at the peak of clinical signs (d16), and during recovery (day 45) compared to normal healthy
control animals. b) Numbers of peripheral Th17 cells increased in sham treated EAE mice, whereas EPO therapy sharply reduced the number of
peripheral Th17 cells in MOG-immunized animals. c) EPO treatment significantly reduced peripheral MOG40–54/H-2Db specific T effector cell
population compared to sham treated EAE mice. Data represents mean6SEM for 6 individual mice. *, p,0.05; **, p,0.001.
doi:10.1371/journal.pone.0001924.g005
Figure 6. EPO treatment increased numbers of Treg cells and reduced numbers of Th17 cells in MOG-EAE mouse spinal cord. MOG-
immunized C57 mice received daily EPO or PBS treatment for 6 days (day 1–6). Spinal cords were obtained at two different time points (day 16 and
day 45) from mice treated with EPO or sham treated with PBS. Cells were quantified for number of Tregs (CD4+Foxp3+), Th17 and MOG-antigen
specific T cells by flow cytometry. a) EPO therapy induced a substantial increase in Foxp3+ Treg cells in EAE spinal cords. The EPO induced expansion
of Tregs in the CNS became even more evident in late stages of the disease and correlated with less severe neurologic deficit. b–c) Foxp3+ labeled
Treg cells in PBS or EPO treated MOG-EAE spinal cord by IHC. Panel b shows a sham treated EAE spinal cord section reacted with Foxp3 antibody
containing few labeled cells. By contrast, many more Foxp3+ cells were present in the infiltrates of EPO treated EAE spinal cord (panel c). d)
Significantly increased numbers of Th17 cells occurred in sham treated EAE mouse spinal cord and this correlated with more severe clinical
neurologic deficits whereas EPO therapy suppressed the number of spinal cord Th17 cells. e) Increased MOG antigen-specific T cells occurred within
untreated EAE spinal cord, and EPO induced large reductions in MOG-specific T effector cells within the CNS. Data represents mean6SEM for 6
individual mice. *, p,0.05; **, P,0.001.
doi:10.1371/journal.pone.0001924.g006
EPO: Immune Modulation
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Since proinflammatory cytokines, especially IL-2, IL-6 and TNF-
a, play significant roles in EAE pathogenesis [20,21,33], we collected
supernatants from either EPO or control media treated cell cultures
and quantified levels of cytokines. Exposure to EPO induced
substantial reductions in all of the major classic pro-inflammatory
cytokines and the reduced cytokine level in EPO treated samples was
associated with decreased numbers of MOG44–54 dimer positive
pathogenic T cells. There were no significant alterations in Th2-type
cytokines such as IL-4 and IL-5 in EPO treated samples compared to
controls. The in vitro EPO-mediated reduction in proinflammatory
cytokines was also dose dependent.
The EPO-mediated non-specific and specific immune modu-
lating effects on peripheral lymphoid tissues in EPO-treated EAE
animals likely contributes to their less severe clinical course. Anti-
inflammatory regulatory T cells have been found to be an
important CD4 cell subpopulation for controlling the development
of autoimmune disease [12,34,35,36,37,38]. Adoptive transfer of
Treg cells has been shown to be of therapeutic efficacy in several
animal autoimmune disease models. Our study shows that short-
term EPO therapy in MOG-immunized mice is associated with
rapid expansion of the Treg cell population in peripheral
lymphoid tissue and this EPO-induced expansion of Treg cells
was sustained over long term follow up. In fact, EPO-treated EAE
animals that manifested delayed onset of clinical disease and less
neurologic damage were found to have higher numbers of Treg
cells within both DILNs and spinal cord. The EPO-induced higher
Treg population may play an important role in reducing the
peripheral immune response to MOG autoantigen, and may be
the major source of Tregs migrating into CNS to minimize
inflammation within CNS white matter. A recent study showed
that anti-inflammatory vasoactive intestinal peptide also prevents
neurologic progression in MOG-EAE by inducing Treg cell
expansion in peripheral lymphoid tissue and the CNS [34].
The other important subpopulation of CD4 helper T cells
recently recognized to be a critical player in inflammatory
autoimmune disease pathogenesis is the IL-17 cell. IL-17 is a
potent proinflammatory cytokine and overproduction of IL-17 has
been associated with a variety of human autoimmune diseases and
their corresponding animal models. The kinetics and organ
distribution of Th17 cells in our MOG35–55 induced EAE mice
was very similar to the Th17 cell kinetics following proteolipid
protein 139–151 peptide induced EAE in SLJ/J mice [39]. Th17
cells, like the MOG40–54 specific T cells, reside mainly in the
peripheral lymphatics during the EAE induction phase after
immunization. Later, when increased numbers of infiltrating
inflammatory cells invade the CNS (12–20 days post MOG-
immunization), Th17 cells, together with MOG-specific T effector
cells, were easily detected in diseased spinal cords. EPO treatment
abrogates the proliferation of peripheral Th17 cells during both
the early induction phase as well as at later stages of EAE, and
EPO treatment inhibits Th17 cell formation within the spinal cord
during both acute and convalescent phases of EAE.
It is unknown by what mechanism EPO suppresses expansion of
the Th17 cell subset in EAE animals. Since IL-6 has been reported to
promote differentiation of naı¨ve CD4 T cells into Th17 cells in vitro,
the level of IL-6 secretion by inflammatory cells could be playing a
crucial role for in vivo development and expansion of Th17 cells
[40]. Our in vitro studies demonstrated significantly reduced IL-6
levels in EPO treated MOG-T cell cultures, suggesting that down-
regulation of Th17 by EPO could be a consequence of reduced IL-6
secretion. A less severe inflammatory environment in peripheral
lymphoid tissue as well as in the CNS after EPO therapy may
prevent significant Th17 migration into the CNS, thereby delaying
disease onset and inducing less severe CNS pathology.
The mechanism and precise signaling pathway by which EPO
suppresses the immune response in the peripheral lymphoid tissues
is also unknown. Since CD 11c expressing dendritic cells are
pivotal in the control of developing immune responses, it may be
that the EPO treatment induced massive 20-fold reduction in
lymphoid dendritic cells coupled with marked down-regulation of
MHC II expression on the surface of mononuclear cells in EAE is
sufficient to block full development of the autoimmune process.
This notion is supported by reports on 3 genetic conditions of mice
where excessive DCs accumulate in the lymphoid tissues (DC-p35,
CD11c-CRE Fas KI, and mice deficient in the immunoreceptor
tyrosine-based inhibitor motif (Dcir)). These animals have greatly
expanded dendritic cell populations; show exaggerated immune
responses and subsequently develop systemic autoimmunity
[41,42,43]. The classic EPO signaling pathway for erythropoiesis
occurs through EPO ligand binding to EPO receptors and
subsequent receptor dimerization, however there are recent
reports claiming that EPO tissue protection is mediated by a
different signaling pathway that involves binding to a hetero
receptor composed of EPO receptor and the common beta
receptor (bcR). The common beta receptor is used for IL-5, IL-3,
and macrophage colony stimulating factor signaling and is
upregulated during inflammatory responses [44] .
Beneficial therapeutic effects of exogenously administered whole
molecule EPO have been described in several animal models of
neurologic injury, including occlusive cerebral vascular disease,
acute brain trauma, epilepsy, as well as in both autoimmune
arthritis and EAE [14,45,46]. However, application of even
medium-term EPO therapy for most acute conditions in humans
remains improbable because EPO therapy may overly stimulate
erythropoiesis with the subsequent risk of thromboembolic
complications. To overcome this concern, whole molecule EPO
administration would have to be limited to very short term use.
Other EPO molecular preparations, such as an asialo-form of
EPO, carbamylated EPO (CEPO), or certain EPO mutants, have
been reported to have protective effects in animals following
experimental traumatic spinal cord injury or acute stroke without
provoking an increase in red cell mass [47,48,49]. We have
synthesized a library of low molecular weight cyclic EPO peptides
that have been tested on the EAE animal model and we have
identified a small domain that blocks paralysis in the acute EAE
animal yet is devoid of hematopoietic effects [50]. This small domain
appears to code for a region that contains most of the immuno/
inflammatory modulating effects described in this report. Our
evidence suggests that distinct functional and structural domain(s) co-
exist within the whole molecule EPO, that retain tissue protective
effects without manifesting hematopoietic side effects.
One of the surprising newly recognized consequences of EPO
therapy in humans that has emerged over the past several years
has been the unexpected negative effect of EPO therapy on
survival in cancer patients [51]. A large clinical trial, the breast
cancer erythropoietin survival trial (BEST) was terminated early
because of an increased number of patients experiencing early
demise in the EPO arm [52]. Poor survival was also reported in a
randomized placebo controlled trial of Epoetin beta for the
treatment of patients with head and neck cancer receiving
radiotherapy [53]. The reason for the decreased cancer patient
survival in these studies is unknown and enhanced tumor growth
induced by signaling to EPO receptors growing on malignant cell
surfaces has been suggested as one possible mechanism. The new
observations described here in our report suggests another
intriguing possibility that remains to be studied - could the
immunomodulatory effects of EPO be contributing to suppress-
ing immune function in the cancer patient?
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In conclusion, we investigated the mechanism behind the
neuroprotective effects of EPO in classic autoimmune EAE
animals and found that EPO has striking pleiotropic immuno-
modulatory effects on the peripheral lymphatic tissues as well as on
the CNS target organ. EPO appears to restrain the overwhelming
autoimmune response in MOG-immunized EAE animals and
restores it to a more balanced immune status. Our studies suggest
that multiple alterations including a reduction in total autoreactive
T cells, DCs, MHC expression as well as an alteration in the
balance between Th17 cells and expanded Treg cell populations
within peripheral lymphoid tissue and CNS all contribute to EPO-
mediated neuroprotection.
Materials and Methods
Mice
C57BL/6 (8–10 weeks old) female mice were purchased from
Charles River Laboratories and maintained in a conventional
facility. The studies were conducted in accordance with the
Animal Component of Research Protocol guidelines at the VA
Hospital, East Orange, NJ, US.
Animal Model of EAE
C57BL/6 mice were immunized subcutaneously at the tail base
with 100 ml (200 mg) of MOG peptide35–55 dissolved in distilled
water and emulsified with an equal volume of complete Freund’s
adjuvant supplemented with 4 mg/ml mycobacterium tuberculo-
sis H37Ra [14]. Immediately after immunization, animals
received an intravenous injection of 200 ng of bordetella pertussis
toxin (List Biological Laboratories, Campbell, CA) in 200 ml PBS.
Animals were weighed daily and assessed for clinical signs of EAE
by two independent observers. We used the same clinical EAE
scoring system to assess neurological deficit in our mouse EAE
model as previously described [14] .
Treatment protocol
EPO (Epoetin Alfa, Ortho Biotech products, LP) in 2,000 U/ml
vial stock was stored at 4uC. Administration of EPO was initiated
either at the time of immunization or delayed until day 7 post-
immunization. Animals were treated with intravenous EPO
(5000 U/kg/day63 days followed by 1000 U/kg/day63 days)
in freshly prepared saline or sham treated for 6 days with an
equal volume of saline.
Mononuclear cell suspensions prepared from peripheral
lymphoid and CNS tissue
At various time-points (before disease onset, at peak disease, and
during recovery or later phases), animals were sacrificed, their
draining inguinal lymph nodes and spleen removed for erythro-
cyte-depleted single-cell suspension preparations. The total MNCs
were quantified subsequently. Mononuclear cells from the spinal
cord were isolated following a published protocol by Korn T et al
[54]. In brief, after perfusion through the left ventricle with cold
PBS the pooled spinal cords from 6 animals were collected from
MOG-immunized mice at each time-point. The spinal cords were
cut into small pieces, minced, and passed through a tissue strainer
and the mononuclear infiltrate obtained by purification through a
Percoll gradient [54].
Antibodies for flow cytometry
Cell surface staining of mouse single cell suspensions was
obtained with mAbs directed against CD3, CD4, CD8, MHC
class I, II and CD11c (BD PharMingen, San Diego, CA). Flow
cytometry was performed on a BD FACScan machine (BD
Biosciences). For intracellular IL-17 or Foxp3 staining, cells were
first reacted with FITC-anti-CD4 or FITC-anti-CD4/APC-anti-
CD25 (eBioscience, San Diego), then washed, fixed and
permeabilized following the manufacturer’s recommendations.
The PE conjugated anti-Foxp3 or anti-IL-17 Mab was subse-
quently added. The samples were subjected to flow cytometry after
multiple washings. Flow cytometry data was analyzed using
CellQuest software and the Flowjo analysis program.
EPO effects on MOG-EAE-specific T cells in tissue culture
MNCs were obtained from EAE mice spleens 5–7 days post
MOG35–55 immunization. T cells were isolated from the single cell
suspensions using MAC pan-T cell beads [55]. The MOG-specific
T cells were then enriched by repeated stimulation with syngeneic
splenic antigen presenting cells pulsed with MOG35–55 peptide
antigen. To determine the biological effect of EPO on antigen
specific T cells and their secreted cytokines, the in vitro enriched
MOG-specific T cells were washed three times with cold PBS and
then incubated with log dilutions of EPO (1, 10 and 100 U/ml) in
culture medium (RPMI1640 supplemented with 10% FCS) for
48–72 hrs. Control cells were incubated with medium alone.
MOG44–54/H2-D
b and control NP366–374/H2-D
b dimers were
freshly prepared by adding the truncated peptides to a
recombinant soluble dimeric mouse H-2Db:IgG1 fusion protein
(BD Pharmingen, San Diego, CA). Cell culture supernatants were
collected from each experimental sample well for cytokine profile
analysis (below). Flow cytometry of either EPO treated cells or
control cells was performed using dual-color staining with peptide
dimer complexes and anti-CD3 mAb to determine the level of
MOG specific effector T cells [19].
Effect of EPO on cytokine levels in MOG-EAE specific T
cell cultures
Luminex technology was used to detect multiple cytokines and
chemokines simultaneously within the pre-treated EAE T cell
culture supernatants (above). Commercial kits (Upstate, Lake
Placid, NY) containing multi-cytokine beads (IL-1b, IL-2, IL-4,
IL-5, IL-6, IL-10, GM-CSF, IL-12, TNFa and IFN-c) were run
with their enclosed buffers and standards, following directions
from the manufacturer. To obtain concentration values, mean
fluorescence intensities from the bead combinations were analyzed
by the MasterPlex QT quantification software.
Immunohistochemistry
Spinal cords were obtained from sham or EPO treated MOG-
EAE animals. Immunohistochemical staining for intracellular
Foxp3 was performed using biotinylated Foxp3 antibody
(eBioscience, San Diego, CA) and an avidin-biotin immunoper-
oxidase detection system on paraffin-embedded spinal cord
sections.
Statistical analysis
Data are presented as the mean6SEM. The Mann-Whitney U
test was used to determine the significance of the intergroup
difference in EAE clinical scores and duration of maximum
neurological deficit. The composite data was analyzed by the
Kruskal-Wallis one-way analysis of variance. Values of p,0.05
were considered significant.
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